Premature Menopause Clinic London

09/09/2026

Balance exercises primarily protect bones by preventing the falls that cause dangerous fractures, while also strengthening the stabilising muscles that support the skeletal system.
To learn balance exercises and safe movements, you can check the guidance provided by the Royal Osteoporosis Society and sign post others who may benefit from it .
The website has loads of useful resources on bone health and osteoporosis.

https://theros.org.uk/information-and-support/exercise/exercise-to-help-your-balance/

08/09/2026

There is so much talk about menopause, hormone changes, lifestyle, cognitive health and risk of dementia. Every few weeks, research studies are published which add a little bit to the existing knowledge.
What do we know with certainty at present and what is uncertain? How do we read the conflicting study results and where are the gaps? How do we counsel patients in clinical settings and what management options do we have?
We will try to address there topics in our upcoming RCGP event on 14th October 2026.

Delegates can expect to -
Understand better the cognitive symptoms of menopause transition and how to recognise them
Familiarise themselves with the current knowledge about evolution of and management options for these symptoms 
Get to know more about non-hormonal interventions for cognitive symptoms 
Discuss the role of hormone replacement therapy in management of cognitive effects of menopause before and after the age of 45

Please join us on the day by clicking the link or search menopause events on the RCGP website to register -
https://engage.rcgp.org.uk/event/a2kWS000000eYPZ/ev07209?recordId=a2kWS000000eYPZ

Thank you Prof Aimee Spector and Dr Alba Soares Pereira for putting this together 🙏🏻.

07/09/2026

Fundraise for Menopause and Cancer CIC (not-for-profit): Make a donation today to support Menopause and Cancer …
Or
Join us on 12th September for the Thames Bridges Trek Ultra Challenge
https://menopauseandcancer.org/thames-bridges-trek/

If you would like to donate -
https://fundraiseformenopauseandcancer.raiselysite.com/vikram-talaulikar Or use the QR code

05/09/2026

Musculoskeletal symptoms involving muscles, bones and joints affect 40-60% during menopause transition and beyond. There is a significant overlap between such symptoms and several rheumatological conditions. Not recognising the possibility of hormone changes causing symptoms can lead to over investigation, misdiagnosis, unnecessary referrals or medications and poor patient satisfaction with clinical care. Equally liaising with the GP and rheumatology teams becomes important when menopause can impact established rheumatological disease.

We talked about this and how hormones could impact various rheumatological conditions (osteoarthritis, rheumatoid arthritis, SLE, psoriatic arthritis, osteoporosis) and the clinical pathway/research gaps that exist currently.

It was wonderful to talk to the attendees at the Royal Society of Medicine yesterday. I enjoyed the QandAs. Grateful to Dr Raj Amarnani and Dr Su-Ann Yeoh at the rheumatology and rehabilitation section of RSM for this opportunity 🙏🏻.

04/09/2026

Worldwide, the incidence of cancer in adolescent and young adults (AYA, 18 to 39 years) has been increasing over time.
The survival rates for young adult cancer survivors have seen significant improvement, largely attributed to advancements in early diagnosis, treatment protocols and specialised oncology care.
However, while survival rates are promising, these developments have not been entirely devoid of complications. Many cancer survivors face a range of long-term effects arising from their treatments, including chronic health issues like cardiovascular disease, metabolic syndrome, reproductive health issues, and psychological distress.

This review from Katharina Egger-Heidrich and team offers a comprehensive approach to survivorship care by examining multiple organ systems and late effects. It provides evidence-based recommendations supported by research and expert consensus. The review also identifies gaps within the current guidelines, and underscores important areas that require further research to enhance surveillance strategies and improve patient outcomes.

Closing these gaps is essential to improving long-term health outcomes and quality of life for adolescent and young adult cancer survivors.

https://www.sciencedirect.com/science/article/pii/S0305737225001148

Please share this survey from Menopause and Cancer CIC (not-for-profit) designed to gather insights from individuals (age 18-30) who have experienced both menopause and cancer with the aim to better understand the unique challenges faced by this community and to use these findings to enhance the support available for those affected 🙏🏼. The more responses we get, better the representation of this community.

Click to fill in or scan the QR code -
https://forms.cloud.microsoft/Pages/ResponsePage.aspx?id=8y1ywoOIqkup1ZOI4kKt2B5ITslOQvhElyTxa010jzlUNUgxWjYxOUtOU1NER0hJNEdDQzZEQ0dJTSQlQCN0PWcu

03/09/2026

Thank you Kiran Singh at The Sattva Collective for the opportunity to share my thoughts about menopause experiences in different healthcare and cultural settings and how we can do better to support those who need help during menopause transition.

https://www.thesattvacollective.org/p/interview-with-dr-vikram-talaulikar?utm_campaign=post&utm_medium=web

02/09/2026

A useful systematic review of literature from Cai et al. on psoriasis (PsO) and psoriatic arthritis (PsA) and the impact of s*x hormones on these closely related inflammatory diseases with marked s*x differences. The authors included a total of 72 studies.

What did they find?
High-oestrogen states (e.g., pregnancy) were associated with improvement or low disease activity in PsO, whereas postpartum phase and menopause were high-risk periods for relapse. Evidence for PsA was limited and inconsistent, although postpartum phase appeared to be a higher-risk window for worsening. Evidence on role of hormone replacement therapy remained inconclusive and appeared to vary by formulation, timing, and population.

The authors concluded that hormone fluctuations (oestrogen and progesterone) across life course influenced disease activity in women, but evidence for hormone-based interventions was limited and inconsistent.

We have certainly come across women in our clinics who have noticed worsening of psoriasis or psoriatic arthritis during menopause. The next step in research is to evaluate if and how and what type of HRT may prevent worsening of symptoms and stabilise the condition.

https://link.springer.com/article/10.1007/s40257-026-01067-6

There is so much more that we need to understand about oestrogen, progesterone and testosterone in relation to many rheumatological conditions. We will talk a bit about it at the meeting on Friday. Do join us if you can at the Royal Society of Medicine.

https://www.rsm.ac.uk/events/rheumatology-and-rehabilitation/2025-26/rru02/

01/09/2026

Every 2-3 months, we at Menopause Research Education Fund (MREF) try to pick 5-6 articles based on latest research into hormones and women’s health and describe the methodology used by researchers and the conclusions of their studies along side the study strengths and limitations.
If you would like to watch, here is the latest episode link -
https://www.youtube.com/live/xx6W_7qKA6U?is=qhurDwNlcj3MGe2H
Or
Search ‘Menopause Research Education Fund’ on YouTube to watch it

Do suggest any studies or topics you would like us to cover next time and we will do our best.

Thank you Menopause Research Education Fund and Fiona Clark 🙏🏻

31/08/2026

30/08/2026

We have been working on some patient information on how to use some of the common transdermal oestrogen hormone replacement therapy (HRT) preparations.
How much do the instructions differ between products? Quite a bit!
Here is what the SmPCs (Summary of Product Characteristics) of the preparations say for optimum product results - see below in chat for each product.

Sandrena gel
Sandrena should be rubbed gently on dry and clean skin. Apply the gel to your lower body or thighs. Apply the gel to a different side of your body each day. Spread the gel over an area 1–2 times the size of your hand. Allow the gel to dry for a few minutes. Do not wash the area where you have applied the gel for at least one hour.
https://www.medicines.org.uk/emc/product/1048/pil

Oestrogel
The gel dose should be dispensed and applied to clean, dry, intact areas of skin e.g. on the arms and shoulders, or inner thighs. A thin layer of the gel should be applied to the entire arm on the inside and outside from wrist to shoulder or inner thigh. The area of application should be as large as possible.
Oestrogel should not be applied on or near the breasts or on the vulval region. A frequent change in application sites is recommended. Washing the skin or contact with other skin products should be avoided until at least one hour after application of Oestrogel. Oestrogel must be allowed to dry for 5 minutes before covering the skin with clothing.
https://www.medicines.org.uk/emc/product/353/smpc

Evorel gel
The correct dose of gel should be dispensed and applied to clean, dry, intact areas of skin e.g. on the arms and shoulders, or inner thighs, preferably after washing in the morning or evening. The area of application should be at least 2 times the size of the hand. Evorel Gel should not be applied on or near the breasts or on the vulval region. A frequent change in application sites is recommended. It is not necessary to rub Evorel Gel in, however, it should be allowed to dry for 2 minutes before covering the skin with clothing. The site of application should not be washed for 60 minutes.
https://www.medicines.org.uk/emc/product/101998/smpc

Lenzetto spray
The container should be held upright and vertical for spraying. The daily dose is one metered-dose spray on the inner forearm. If two or three sprays are prescribed as the daily dose, they should be applied to adjacent non-overlapping (side-by-side) 20 cm2 areas on the inner surface of the arm between the elbow and the wrist and allowed to dry for approximately 2 minutes. The site of application should not be washed for 60 minutes.
https://www.medicines.org.uk/emc/product/11175/smpc

Evorel patches
Evorel should be applied to the skin as soon as it is removed from the wrapper. Recommended application sites are on clean, dry, healthy, intact skin and each application should be made to a slightly different area of skin on the trunk below waistline. Evorel should not be applied on or near the breasts.
Evorel should remain in place during bathing and showering. Should it fall off during bathing or showering the patient should wait until cutaneous vasodilation ceases before applying a replacement patch to avoid potential excessive absorption. Should a patch fall off at other times it should be replaced immediately. Patients can be advised to use baby oil to help remove any gum/glue which may remain on their skin after patch removal.
https://www.medicines.org.uk/emc/product/10927/smpc

Estradot patches
The adhesive side of Estradot should be placed on a clean, dry area of the abdomen. Estradot should not be applied to the breasts.
Estradot should be replaced twice weekly. The site of application must be rotated, with an interval of at least 1 week allowed between applications to a particular site. The area selected should not be oily, damaged, or irritated. The waistline should be avoided, since tight clothing may dislodge the patch. The patch should be applied immediately after opening the sachet and removing the protective liner. The patch should be pressed firmly in place with the palm of the hand for about 10 seconds, making sure there is good contact, especially around the edges.
In the event that a patch should fall off, the same patch may be reapplied. If necessary, a new patch may be applied.
https://www.medicines.org.uk/emc/product/7226/smpc